Clinical Trials Browser

Terminated × INDUSTRY × Panobinostat × Clear all

NCT00490776 2021-08-18

Study of Oral LBH589 in Adult Participants With Refractory/Resistant Cutaneous T-Cell Lymphoma (CTCL)

Phase 2 Terminated

9 enrolled 6 charts

DermatologicLymphoid

Mycosis Fungoides, Sezary Syndrome, Lymphoma, T-Cell, Cutaneous

NCT00449761 2021-07-15

Efficacy and Safety of LBH589B in Adult Patients With Refractory Chronic Myeloid Leukemia in Accelerated or Blast Phase

Phase 2 Terminated

27 enrolled 14 charts

MyeloidOther hematologic neoplasm

Blast Crisis, Leukemia, Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT00445068 2021-07-14

Efficacy and Safety of LBH589B in Adult Patients With Multiple Myeloma

Phase 2 Terminated

38 enrolled 13 charts

Multiple Myeloma

NCT00493766 2020-12-19

Safety of LBH589 Alone and in Combination With IV Docetaxel and Prednisone

Phase 1 Terminated

Prostatic Neoplasms

NCT02720510 2018-07-24

PANORAMA4

Phase 2 Terminated

6 enrolled 7 charts

Multiple Myeloma

NCT00567879 2016-05-09

A Trial of Panobinostat and Trastuzumab for Adult Female Patients With HER2 Positive Metastatic Breast Cancer (MBC) Whose Disease Has Progressed on or After Trastuzumab

Phase 1/2 Terminated

56 enrolled 5 charts

Breast Neoplasms

NCT00699296 2012-11-27

Study of Oral LBH589 in Patients With Cutaneous T-cell Lymphoma and Adult T-cell Leukemia/Lymphoma

Phase 2 Terminated

DermatologicLymphoidOther hematologic neoplasm

Leukemia-Lymphoma, Adult T-Cell, Lymphoma, T-Cell, Cutaneous

NCT00419536 2010-04-08

Safety of LBH589 Alone and in Combination With Intravenous Docetaxel and Prednisone

Phase 1 Terminated

Prostatic Neoplasms